Alkermes Plc Operating Income Over Time
| ALKS Stock | USD 34.88 0.99 2.92% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Alkermes Plc Performance and Alkermes Plc Correlation. Is there potential for Biotechnology market expansion? Will Alkermes introduce new products? Factors like these will boost the valuation of Alkermes Plc. If investors know Alkermes will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Alkermes Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.12) | Earnings Share 1.95 | Revenue Per Share | Quarterly Revenue Growth 0.042 | Return On Assets |
Investors evaluate Alkermes Plc using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Alkermes Plc's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Alkermes Plc's market price to deviate significantly from intrinsic value.
Understanding that Alkermes Plc's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alkermes Plc represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Alkermes Plc's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Operating Income Analysis
Compare Alkermes Plc and related stocks such as PTC Therapeutics, Arcellx, and Protagonist Therapeutics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PTCT | 30.6 M | 30.6 M | (26.8 M) | (45.4 M) | (99.4 M) | (167.1 M) | (132.1 M) | (64.3 M) | (115.7 M) | (241.2 M) | (431.8 M) | (374.4 M) | (447.4 M) | (439.5 M) | (302.6 M) | (272.3 M) | (285.9 M) |
| ACLX | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (18 M) | (32.1 M) | (65 M) | (191.3 M) | (89.9 M) | (137.6 M) | (123.8 M) | (130 M) |
| PTGX | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (14.8 M) | (32.7 M) | (37.9 M) | (42.3 M) | (80.5 M) | (64.5 M) | (125.8 M) | (131.4 M) | (93.7 M) | 252.8 M | 290.8 M | 305.3 M |
| ACAD | (11.3 M) | (22.9 M) | (20.9 M) | (38.3 M) | (93.2 M) | (164.6 M) | (272.8 M) | (292.4 M) | (247.4 M) | (246.5 M) | (286.6 M) | (170.4 M) | (223.6 M) | (73.4 M) | 230.8 M | 207.7 M | 218.1 M |
| TGTX | (3.8 M) | (882 K) | (26.9 M) | (23 M) | (55.7 M) | (63.2 M) | (79 M) | (118.7 M) | (174.4 M) | (169.1 M) | (273.6 M) | (344.8 M) | (218.3 M) | 20.6 M | 41.9 M | 37.7 M | 39.6 M |
| ARWR | (158.6 K) | (21.1 M) | (24.6 M) | (53.3 M) | (96 M) | (81.7 M) | (37 M) | (55.9 M) | 61.2 M | (93.2 M) | (149 M) | (178.5 M) | (205 M) | (601.1 M) | 98.3 M | 88.5 M | 92.9 M |
| PCVX | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (35.5 M) | (54.2 M) | (89.6 M) | (103.7 M) | (232.3 M) | (468 M) | (569.5 M) | (512.6 M) | (487 M) |
| CRSP | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (25.7 M) | (68.1 M) | (64.6 M) | (158.9 M) | 46.7 M | (354.4 M) | 373.5 M | (673.2 M) | (222.5 M) | (466.6 M) | (419.9 M) | (398.9 M) |
| KYMR | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (21.5 M) | (42.2 M) | (46.3 M) | (100.5 M) | (161.3 M) | (165.5 M) | (261.6 M) | (235.5 M) | (223.7 M) |
Alkermes Plc and related stocks such as PTC Therapeutics, Arcellx, and Protagonist Therapeutics Operating Income description
Operating Income is the amount of profit realized from Alkermes Plc operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Alkermes Plc is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Alkermes Plc | ALKS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Connaught House, Dublin, |
| Exchange | NASDAQ Exchange |
USD 34.88
Additional Tools for Alkermes Stock Analysis
When running Alkermes Plc's price analysis, check to measure Alkermes Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alkermes Plc is operating at the current time. Most of Alkermes Plc's value examination focuses on studying past and present price action to predict the probability of Alkermes Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alkermes Plc's price. Additionally, you may evaluate how the addition of Alkermes Plc to your portfolios can decrease your overall portfolio volatility.